NCPD Article

Hepatic Sinusoidal Obstruction Syndrome in Patients Undergoing Hematopoietic Stem Cell Transplant

Seth Eisenberg

hematopoietic stem cell transplantation
ONF 2008, 35(3), 385-397. DOI: 10.1188/08.ONF.385-397

Purpose/Objectives: To provide a comprehensive review of hepatic sinusoidal obstruction syndrome (HSOS) in patients receiving a hematopoietic stem cell transplant and to describe the implications for nursing care.

Data Sources: Published research articles, reviews, case reports, and books.

Data Synthesis: Disagreement exists regarding the precise cause of HSOS. Prevention and treatment strategies have emerged based on these causative theories. Few published resources are available for nursing assessment and intervention specific to HSOS, although symptom management strategies derived from other disease etiologies can be used successfully.

Conclusions: HSOS is a complex consequence of myeloablative chemoradiotherapy. Although the overall incidence is declining, research continues to explore better methods for prophylaxis and develop more efficacious treatment options.

Implications for Nursing: Nurses caring for patients receiving a hematopoietic stem cell transplant must comprehend the proposed etiologies for HSOS and be familiar with the manifestations of the syndrome. Symptom management requires a thorough understanding of affected organ systems.

Jump to a section


    Attal, M., Huguet, F., Rubie, H., Huynh, A., Charlet, J. P., Payen, J. L., et al. (1992). Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: A prospective, randomized trial. Blood, 79(11), 2834-2840.
    Bairey, O., Kirgner, I., Yakobi, M., Hamdan, A., Ben-Ari, Z., & Shaklai, M. (2002). Clinical severe hepatic veno-occlusive disease during induction treatment of acute monoblastic leukemia managed with defibrotide. American Journal of Hematology, 69(4), 281-284.
    Bajwa, R. P., Cant, A. J., Abinun, M., Flood, T. J., Hodges, S., Hale, J. P., et al. (2003). Recombinant tissue plasminogen activator for treatment of hepatic veno-occlusive disease following bone marrow transplantation in children: Effectiveness and a scoring system for initiating treatment. Bone Marrow Transplantation, 31(7), 591-597.
    Batsis, I., Yannaki, E., Kaloyannidis, P., Sakellari, I., Smias, C., Georgoulis, I., et al. (2006). Veno-occlusive disease prophylaxis with fresh frozen plasma and heparin in bone marrow transplantation. Thrombosis Research, 118(5), 611-618.
    Bearman, S. I. (1995). The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood, 85(11), 3005-3020.
    Bearman, S. I. (2000). Veno-occlusive disease of the liver. Current Opinion in Oncology, 12(2), 103-109.
    McDonald, G. B., Slattery, J. T., Bouvier, M. E., Ren, S., Batchelder, A. L., Kalhorn, T. F., et al. (2003). Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood, 101(5), 2043-2048.
    Metheny, N. (2000). Fluid and electrolyte balance: Nursing considerations (4th ed., pp. 353-363), Philadelphia, PA: Lippincott Williams & Wilkins.
    Mudge, C., & Carlson, L. (1992). Hepatorenal syndrome. AACN Clinical Issues in Critical Care Nursing, 3(3), 614-632.
    Nurnberger, W., Michelmann, I., Burdach, S., & Gobel, U. (1998). Endothelial dysfunction after bone marrow transplantation: Increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications. Annals of Hematology, 76(2), 61-65.
    Or, R., Nagler, A., Shpilberg, O., Elad, S., Naparstek, E., Kapelushnik, J., et al. (1996). Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation, 61(7), 1067-1071.
    Park, S. H., Lee, M. H., Lee, H., Kim, H. S., Kim, K., Kim, W. S., et al. (2002). A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplantation, 29(2), 137-143.
    Patton, D. F., Harper, J. L., Wooldridge, T. N., Gordon, B. G., Coccia, P., & Haire, W. D. (1996). Treatment of veno-occlusive disease of the liver with bolus tissue plasminogen activator and continuous infusion antithrombin III concentrate. Bone Marrow Transplantation, 17(3), 443-447.
    Peck, S. N., & Griffith, D. J. (1988). Reducing portal hypertension and variceal bleeding. Dimensions of Critical Care Nursing, 7(5), 269-279.
    Pegram, A. A., & Kennedy, L. D. (2001). Prevention and treatment of veno-occlusive disease. Annals of Pharmacotherapy, 35(7-8), 935-942.
    Pierson, D. J. (2006). Respiratory considerations in the patient with renal failure. Respiratory Care, 51(4), 413-422.
    Rajvanshi, P., Shulman, H. M., Sievers, E. L., & McDonald, G. B. (2002). Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood, 99(7), 2310-2314.
    Reiss, U., Cowan, M., McMillan, A., & Horn, B. (2002). Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: Incidence, risk factors, and outcome in a cohort of 241 patients. Journal of Pediatric Hematology/Oncology, 24(9), 746-750.
    Rhiner, M., & Slatkin, N. (2006). Pruritis, fever, and sweats. In B. Ferrell & N. Coyle (Eds.), Textbook of palliative nursing (2nd ed., pp. 345-363). Oxford: Oxford University Press.
    Richardson, P. G, Elias, A. D, Krishnan, A., Wheeler, C., Nath, R., Hoppensteadt, D., et al. (1998). Treatment of severe veno-occlusive disease with defibrotide: Compassionate use results in response without significant toxicity in a high-risk population. Blood, 92(3), 737-744.
    Richardson, P. G, Murakami, C., Jin, Z., Warren, D., Momtaz, P., Hoppensteadt, D., et al. (2002). Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: Response without significant toxicity in a high-risk population and factors predictive of outcome. Blood, 100(13), 4337-4343.
    Ringden, O., Remberger, M., Lehmann, S., Hentschke, P., Mattsson, J., Klaesson, S., et al. (2000). N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation. Bone Marrow Transplant, 25(9), 993-996.
    Roper, M. (1996). Back to basics assessing orthostatic vital signs. American Journal of Nursing, 96(8), 43-46.
    Rosenthal, J., Sender, L., Secola, R., Killen, R., Millerick, M., Murphy, L., et al. (1996). Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation. Bone Marrow Transplantation, 18(1), 185-191.
    Rubenfeld, G. D., & Crawford, S. W. (1996). Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: A case for evidence-based guidelines. Annals of Internal Medicine, 125(8), 625-633.
    Russell, J. A., Tran, H. T., Quinlan, D., Chaudhry, A., Duggan, P., Brown, C., et al. (2002). Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomes. Biology of Blood and Marrow Transplantation, 8(9), 468-476.
    Ruutu, T., Eriksson, B., Remes, K., Juvonen, E., Volin, L., Remberger, M., et al. (2002). Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood, 100(6), 1977-1983.
    Saria, M. G., & Gosselin-Acomb, T. K. (2007). Hematopoietic stem cell transplantation: Implications for critical care nurses. Clinical Journal of Oncology Nursing, 11(1), 53-63.
    Sartori, M. T., Spiezia, L., Cesaro, S., Messina, C., Paris, M., Pillon, M., et al. (2005). Role of fibrinolytic and clotting parameters in the diagnosis of liver veno-occlusive disease after hematopoietic stem cell transplantation in a pediatric population. Thrombosis and Haemostasis, 93(4), 682-689.
    Schriber, J., Milk, B., Shaw, D., Christiansen, N., Baer, M., Slack, J., et al. (1999). Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation. Bone Marrow Transplantation, 24(12), 1311-1314.
    Shawcross, D., & Jalan, R. (2005). Dispelling myths in the treatment of hepatic encephalopathy. Lancet, 365(9457), 431-433.
    Shulman, H. M., Fisher, L. B., Schoch, H. G., Henne, K. W., & McDonald, G. B. (1994). Veno-occlusive disease of the liver after marrow transplantation: Histological correlates of clinical signs and symptoms. Hepatology, 19(5), 1171-1181.
    Shulman, H. M., McDonald, G. B., Matthews, D., Doney, K. C., Kopecky, K. J., Gauvreau, J. M., et al. (1980). An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology, 79(6), 1178-1191.
    Siconolfi, L. A. (1995). Clarifying the complexity of liver function tests. Nursing, 25(5), 39-44.
    Simon, M., Hahn, T., Ford, L. A., Anderson, B., Swinnich, D., Baer, M. R., et al. (2001). Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: Possible beneficial use of low molecular weight heparin. Bone Marrow Transplantation, 27(6), 627-633.
    Sjoo, F., Aschan, J., Barkholt, L., Hassan, Z., Ringden, O., & Hassan, M. (2003). N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation. Bone Marrow Transplantation, 32(4), 349-354.
    Smith, L. H., Dixon, J. D., Stringham, J. R., Eren, M., Elokdah, H., Crandall, D. L., et al. (2006). Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood, 107(1), 132-134.
    Song, J. S., Seo, J. J., Moon, H. N., Ghim, T., & Im, H. J. (2006). Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children. Journal of Korean Medical Science, 21(5), 897-903.
    Soubani, A. O. (2006). Critical care considerations of hematopoietic stem cell transplantation. Critical Care Medicine, 34(9 Suppl.), S251-S267.
    Srivastava, A., Poonkuzhali, B., Shaji, R. V., George, B., Mathews, V., Chandy, M., et al. (2004). Glutathione S-transferase M1 polymorphism: A risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood, 104(5), 1574-1577.
    Stark, J. L. (1994). Interpreting BUN/creatinine levels: It's not as simple as you think. Nursing, 24(9), 58-61.
    Tasota, F. J., & Tate, J. (2000). Assessing renal function. Nursing, 30(5), 20.
    Tay, J., Tinmouth, A., Fergusson, D., Huebsch, L., & Allan, D. S. (2007). Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 13(2), 206-217.
    Tefferi, A., Kumar, S., Wolf, R. C., Lacy, M. Q., Inwards, D. J., Gloor, J. M., et al. (2001). Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplantation, 28(10), 997-999.
    Wadleigh, M., Ho, V., Momtaz, P., & Richardson, P. (2003). Hepatic veno-occlusive disease: Pathogenesis, diagnosis and treatment. Currrent Opinion in Hematology, 10(6), 451-462.
    Wadleigh, M., Richardson, P. G., Zahrieh, D., Lee, S. J., Cutler, C., Ho, V., et al. (2003). Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood, 102(5), 1578-1582.
    Weiss, L., Reich, S., Zeira, M., Or, R., Resnick, I. B., Slavin, S., et al. (2007). N-acetylcysteine mildly inhibits the graft-versus-leukemia effect but not the lymphokine activated cells (LAK) activity. Transplant Immunology, 17(3), 198-202.
    Wingard, J. R., Nichols, W. G., & McDonald, G. B. (2004). Supportive care. Hematology, 372-389.
    Winkelman, L. (2004). Malignant ascites. In C. Yarbro, M. Frogge, & M. Goodman (Eds.), Cancer symptom management (pp. 401-412). Sudbury, MA: Jones and Bartlett.
    Wujcik, D., Ballard, B., & Camp-Sorrell, D. (1994). Selected complications of allogeneic bone marrow transplantation. Seminars in Oncology Nursing, 10(1), 28-41.
    Zager, R. A. (1994). Acute renal failure in the setting of bone marrow transplantation. Kidney International, 46(5), 1443-1458.
    Fisher, D. C., Vredenburgh, J. J., Petros, W. P., Hussein, A., Berry, D. A., Elkordy, M., et al. (1998). Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver. Bone Marrow Transplant, 21(2), 117-122.
    Fisher, V., Barnes, Y. J., & Nuss, S. L. (2006). Pretransplant conditioning in adults and children: Dose assurance with intravenous busulfan [Online Exclusive]. Oncology Nursing Forum, 33(2), E36-E43. Retrieved April 3, 2008, from…
    Ford, R., McClain, K., & Cunningham, B. A. (1983). Veno-occlusive disease following marrow transplantation. Nursing Clinics of North America, 18(3), 563-568.
    Gharib, M. I., Bulley, S. R., Doyle, J. J., & Wynn, R. F. (2006). Venous occlusive disease in children. Thrombosis Research, 118(1), 27-38.
    Gines, P., Guevara, M., Arroyo, V., & Rodes, J. (2003). Hepatorenal syndrome. Lancet, 362(9398), 1819-1827.
    Gluckman, E., Jolivet, I., Scrobohaci, M. L., Devergie, A., Traineau, R., Bourdeau-Esperou, H., et al. (1990). Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation. British Journal of Haematology, 74(3), 277-281.
    Gooley, T. A., Rajvanshi, P., Schoch, H. G., & McDonald, G. B. (2005). Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation. Hepatology, 41(2), 345-352.
    Goringe, A. P., Brown, S., O'Callaghan, U., Rees, J., Jebb, S., Elia, M., et al. (1998). Glutamine and vitamin E in the treatment of hepatic veno-occlusive disease following high-dose chemotherapy. Bone Marrow Transplant, 21(8), 829-832.
    Grandt, N. C. (1989). Hepatic veno-occlusive disease following bone marrow transplantation. Oncology Nursing Forum, 16(6), 813-817.
    Hagglund, H., Remberger, M., Klaesson, S., Lonnqvist, B., Ljungman, P., & Ringden, O. (1998). Norethisterone treatment, a major risk factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood, 92(12), 4568-4572.
    Haire, W. D., Ruby, E. I., Gordon, B. G., Patil, K. D., Stephens, L. C., Kotulak, G. D., et al. (1995). Multiple organ dysfunction syndrome in bone marrow transplantation. JAMA, 274(16), 1289-1295.
    Haire, W. D., Ruby, E. I., Stephens, L. C., Reed, E., Tarantolo, S. R., Pavletic, Z. S., et al. (1998). A prospective randomized double-blind trial of anti-thrombin III concentrate in the treatment of multiple-organ dysfunction syndrome during hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 4(3), 142-150.
    Han, M. K., & Hyzy, R. (2006). Advances in critical care management of hepatic failure and insufficiency. Critical Care Medicine, 34(9 Suppl.), S225-S231.
    Hartman, A. R., Williams, S. F., & Dillon, J. J. (1998). Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide versus total body irradiation: A meta-analysis. Bone Marrow Transplantation, 22(5), 439-443.
    Hassan, Z., Hellstrom-Lindberg, E., Alsadi, S., Edgren, M., Hagglund, H., & Hassan, M. (2002). The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo. Bone Marrow Transplantation, 30(3), 141-147.
    Haussmann, U., Fischer, J., Eber, S., Scherer, F., Seger, R., & Gungor, T. (2006). Hepatic veno-occlusive disease in pediatric stem cell transplantation: Impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. Haematologica, 91(6), 795-800.
    Helmy, A. (2006). Review article: Updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome. Alimentary Pharmacology and Therapeutics, 23(1), 11-25.
    Hoekstra, R., Eskens, F. A., & Verweij, J. (2001). Matrix metalloproteinase inhibitors: Current developments and future perspectives. The Oncologist, 6(5), 415-427.
    Hogan, W. J., Maris, M., Storer, B., Sandmaier, B. M., Maloney, D. G., Schoch, H. G., et al. (2004). Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood, 103(1), 78-84.
    Hong, R. W., Rounds, J. D., Helton, W. S., Robinson, M. K., & Wilmore, D. W. (1992). Glutamine preserves liver glutathione after lethal hepatic injury. Annals of Surgery, 215(2), 114-119.
    Horn, B., Reiss, U., Matthay, K., McMillan, A., & Cowan, M. (2002). Veno-occlusive disease of the liver in children with solid tumors undergoing autologous hematopoietic progenitor cell transplantation: A high incidence in patients with neuroblastoma. Bone Marrow Transplant, 29(5), 409-415.
    Ibrahim, R. B., Peres, E., Dansey, R., Abidi, M. H., Abella, E. M., & Klein, J. (2004). Antithrombin III in the management of hematopoietic stem-cell transplantation-associated toxicity. Annals of Pharmacotherapy, 38(6), 1053-1059.
    Iguchi, A., Kobayashi, R., Yoshida, M., Kobayashi, K., Matsuo, K., Kitajima, I., et al. (2001). Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation. Bone Marrow Transplantation, 27(11), 1173-1180.
    Imran, H., Tleyjeh, I. M., Zirakzadeh, A., Rodriguez, V., & Khan, S. P. (2006). Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation: A systematic review and meta-analysis. Bone Marrow Transplantation, 37(7), 677-686.
    Jakubik, L. D., Cockerham, J., Altmann, A. R., & Grossman, M. B. (2003). The ABCs of pediatric laboratory interpretation: Understanding the CBC with differential and LFTs. Pediatric Nursing, 29(2), 97-103.
    Johnson, G., & Quiett, K. (2004). Hematologic effects. In S. Ezzone (Ed.), Hematopoietic stem cell transplantation: A manual for nursing practice (pp. 133-145). Pittsburgh, PA: Oncology Nursing Society.
    Jones, R. J., Lee, K. S., Beschorner, W. E., Vogel, V. G., Grochow, L. B., Braine, H. G., et al. (1987). Venoocclusive disease of the liver following bone marrow transplantation. Transplantation, 44(6), 778-783.
    Kalayoglu-Besisik, S., Yenerel, M. N., Caliskan, Y., Ozturk, S., Besisik, F., & Sargin, D. (2005). Time-related changes in the incidence, severity, and clinical outcomes of hepatic veno-occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years. Transplant Proceedings, 37(5), 2285-2289.
    Kashyap, A., Wingard, J., Cagnoni, P., Roy, J., Tarantolo, S., Hu, W., et al. (2002). Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biology of Blood and Marrow Transplantation, 8(9), 493-500.
    Keller, C. (2001). Bone marrow and stem cell transplantation. In S. Otto (Ed.), Oncology nursing (4th ed., pp. 731-759). Philadelphia, PA: Mosby.
    Kornblum, N., Ayyanar, K., Benimetskaya, L., Richardson, P., Iacobelli, M., & Stein, C. A. (2006). Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucleotides with life-saving activity in severe hepatic veno-occlusive disease: Clinical outcomes and potential mechanisms of action. Oligonucleotides, 16(1), 105-114.
    Kumar, S., DeLeve, L. D., Kamath, P. S., & Tefferi, A. (2003). Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clinic Proceedings, 78(5), 589-598.
    Lapierre, V., Mahe, C., Auperin, A., Stambouli, F., Oubouzar, N., Tramalloni, D., et al. (2005). Platelet transfusion containing ABO-incompatible plasma and hepatic veno-occlusive disease after hematopoietic transplantation in young children. Transplantation, 80(3), 314-319.
    Lee, J., Choi, S., Lee, J., Kim, S., Park, C., Chi, H., et al. (2005). Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Annals of Hematology, 84(5), 321-330.
    Lee, J. L., Gooley, T., Bensinger, W., Schiffman, K., & McDonald, G. B. (1999). Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: Incidence, risk factors, and outcome. Biology of Blood and Marrow Transplantation, 5(5), 306-315.
    Lin, E. M., Tierney, D. K., & Stadtmauer, E. A. (1993). Autologous bone marrow transplantation. A review of the principles and complications. Cancer Nursing, 16(3), 204-213.
    Litzow, M. R., Repoussis, P. D., Schroeder, G., Schembri-Wismayer, D., Batts, K. P., Anderson, P. M., et al. (2002). Veno-occlusive disease of the liver after blood and marrow transplantation: Analysis of pre- and post-transplant risk factors associated with severity and results of therapy with tissue plasminogen activator. Leukemia and Lymphoma, 43(11), 2099-2107.
    Marik, P. E. (2002). Low-dose dopamine: A systematic review. Intensive Care Medicine, 28(7), 877-883.
    Marsa-Vila, L., Gorin, N. C., Laporte, J. P., Labopin, M., Dupuy-Montbrun, M. C., Fouillard, L., et al. (1991). Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation. European Journal of Haematology, 47(5), 346-354.
    McConn, R. (1987). Skin changes following bone marrow transplantation. Cancer Nursing, 10(2), 82-84.
    McCune, J. S., Batchelder, A., Deeg, H. J., Gooley, T., Cole, S., Phillips, B., et al. (2007). Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: Pharmacokinetics, liver toxicity, and mortality. Biology of Blood and Marrow Transplantation, 13(7), 853-862.
    McDonald, G. B. (2006). Advances in prevention and treatment of hepatic disorders following hematopoietic cell transplantation. Best Practice and Research Clinical Haematology, 19(2), 341-352.
    McDonald, G. B., Hinds, M. S., Fisher, L. D., Schoch, H. G., Wolford, J. L., Banaji, M., et al. (1993). Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Annals of Internal Medicine, 118(4), 255-267.
    McDonald, G. B., Sharma, P., Matthews, D. E., Shulman, H. M., & Thomas, E. D. (1984). Venocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors. Hepatology, 4(1), 116-122.
    Bearman, S. I., Anderson, G. L., Mori, M., Hinds, M. S., Shulman, H. M., & McDonald, G. B. (1993). Venoocclusive disease of the liver: Development of a model for predicting fatal outcome after marrow transplantation. Journal of Clinical Oncology, 11(9), 1729-1736.
    Bearman, S. I., Lee, J. L., Baron, A. E., & McDonald, G. B. (1997). Treatment of hepatic veno-occlusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood, 89(5), 1501-1506.
    Bellomo, R., Chapman, M., Finfer, S., Hickling, K., & Myburgh, J. (2000). Low-dose dopamine in patients with early renal dysfunction: A placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet, 356(9248), 2139-2143.
    Berg, J. (1990). Assessing for pericarditis in the end-stage renal disease patient. Dimensions of Critical Care Nursing, 9(5), 266-271.
    Bixby, M. (2006). Third-spacing: Where has all the fluid gone? Nursing made incredibly easy! 42-53. Retrieved July 12, 2007, from OVID.
    Bosonnet, L. (2003). Pruritis: Scratching the surface. European Journal of Cancer Care, 12(2), 162-165.
    Bradley, J. G., & Davis, K. A. (2003). Orthostatic hypotension. American Family Physician, 68(12), 2393-2398.
    Bras, G., Berry, D. M., & Gyorgy, P. (1957). Plants as aetiological factor in veno-occlusive disease of the liver. Lancet, 272(6976), 960-962.
    Brown, S. A., Goringe, A., Fegan, C., Davies, S. V., Giddings, J., Whittaker, J. A., et al. (1998). Parenteral glutamine protects hepatic function during bone marrow transplantation. Bone Marrow Transplant, 22(3), 281-284.
    Carreras, E. (2000). Veno-occlusive disease of the liver after hemopoietic cell transplantation. European Journal of Haematology, 64(5), 281-291.
    Carreras, E., Bertz, H., Arcese, W., Vernant, J. P., Tomas, J. F., Hagglund, H., et al. (1998). Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: A prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood, 92(10), 3599-3604.
    Cesaro, S., Pillon, M., Talenti, E., Toffolutti, T., Calore, E., Tridello, G., et al. (2005). A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Haematologica, 90(10), 1396-1404.
    Chalandon, Y., Roosnek, E., Mermillod, B., Newton, A., Ozsahin, H., Wacker, P., et al. (2004). Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation, 10(5), 347-354.
    Chikotas, N., Gunderman, A., & Oman, T. (2006). Uremic syndrome and end-stage renal disease: Physical manifestations and beyond. Journal of the American Academy of Nurse Practitioners, 18(5), 195-202.
    Cho, Y. H., Lim, H. A., Lee, M. H., Kim, I., Lee, J. S., Park, S., et al. (2007). Pharmacokinetics and tolerability of intravenous busulfan in hematopoietic stem cell transplantation. Clinical Transplantation, 21(3), 417-422.
    Coppell, J. A., Brown, S. A., & Perry, D. J. (2003). Veno-occlusive disease: Cytokines, genetics, and haemostasis. Blood Reviews, 17(3), 63-70.
    Corbacioglu, S., Greil, J., Peters, C., Wulffraat, N., Laws, H. J., Dilloo, D., et al. (2004). Defibrotide in the treatment of children with veno-occlusive disease (VOD): A retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant, 33(2), 189-195.
    de Jonge, M. E., Huitema, A. D., Beijnen, J. H., & Rodenhuis, S. (2006). High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. British Journal of Cancer, 94(9), 1226-1230.
    DeLeve, L. D. (1996). Cellular target of cyclophosphamide toxicity in the murine liver: Role of glutathione and site of metabolic activation. Hepatology, 24(4), 830-837.
    DeLeve, L. D., Shulman, H. M., & McDonald, G. B. (2002). Toxic injury to hepatic sinusoids: Sinusoidal obstruction syndrome (veno-occlusive disease). Seminars in Liver Disease, 22(1), 27-42.
    DeLeve, L. D., Wang, X., Kanel, G. C., Ito, Y., Bethea, N. W., McCuskey, M. K., et al. (2003). Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndrome. Hepatology, 38(4), 900-908.
    Dey, B. R., Shaffer, J., Yee, A. J., McAfee, S., Caron, M., Power, K., et al. (2007). Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen. Bone Marrow Transplant, 40(1), 19-27.
    Dignan, F., Gujral, D., Ethell, M., Evans, S., Treleaven, J., Morgan, G., et al. (2007). Prophylactic defibrotide in allogeneic stem cell transplantation: Minimal morbidity and zero mortality from veno-occlusive disease. Bone Marrow Transplantation, 40(1), 79-82.
    Ezzone, S., & Schmit-Pokorny, K. (2007). Blood and marrow stem cell transplantation: Principles, practice, and nursing insights. Sudbury, MA: Jones and Bartlett.
    Faint, V. (2006). The pathophysiology of hepatic encephalopathy. Nursing in Critical Care, 11(2), 69-74.